Progress of Biological Agents on Psoriatic Arthritis

Author(s): Yan Li, Dashan Wang, Yantang Wang, Guixiu Shi.

Journal Name: Current Pharmaceutical Biotechnology

Volume 15 , Issue 6 , 2014

Become EABM
Become Reviewer

Abstract:

Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.

Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 15
ISSUE: 6
Year: 2014
Page: [525 - 534]
Pages: 10
DOI: 10.2174/138920101506140910150227
Price: $58

Article Metrics

PDF: 36